First, by virtue of the possibility of inducing CD8+ T cell immunity against different antigens contemporarily, the Nefmut-based antitumor strategy would efficiently counteract the tumor cell escape phenomenon often occurring in immunotherapies targeting a single tumor marker. This evidence concerns the gene CD8A and neoplasm.